Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver ...
PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), ...
PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25 th Conference of the Asian ...
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results